Efficacy and Outcomes of Neodymium-doped Yttrium Aluminum Garnet (Nd: YAG) Laser Capsulotomy Performed by Optometrists

Neodymium-doped Yttrium Aluminum Garnet (Nd: YAG) Laser Capsulotomy: Efficacy and Outcomes Performed by Optometrists

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04027595

Enrollment

200

Registered

2019-07-22

Start date

2019-09-17

Completion date

2022-09-30

Last updated

2022-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Posterior Capsule Opacification Obscuring Vision

Brief summary

The purpose of this study is to formally assess the efficacy and outcomes of optometrist-performed neodymium-doped yttrium aluminum garnet (Nd: YAG) laser capsulotomy procedures.

Detailed description

Participants will undergo a pre-procedure examination to establish baseline findings and to determine if they meet the inclusion criteria. Participants will undergo the Nd: YAG laser capsulotomy procedure and will be examined at 1 hour, 1 day (if necessary), 1 week, 1 month, and 3 months following the procedure. Follow-up examinations will evaluate visual acuity improvement and possible post-procedure complications. The complication rate following the laser capsulotomy procedure is typically minimal.

Interventions

PROCEDURENeodymium-doped Yttrium Aluminum Garnet (Nd: YAG) Laser Capsulotomy

A Nd: YAG laser will be used to open the cloudy posterior capsule of the lens to improve central visual acuity.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Ability to provide written informed consent; 2. At least 18 years of age, male or female; 3. Prior cataract surgery; 4. Diagnosed with posterior capsule opacification obstructing vision; 5. Best-corrected visual acuity less than 20/40 or visual acuity with glare that reduces by 2 lines or more on an ETDRS visual acuity chart or significant effect on activities of daily living

Exclusion criteria

1. History of underlying ocular disease (not including mild/moderate non-proliferative diabetic retinopathy or incidental findings) 2. Previous myopic refractive error greater than 6.00 diopters 3. Complications following previous ocular procedures (i.e. intraocular lens decentration) 4. Ocular surgery other than uncomplicated cataract or uncomplicated refractive surgery

Design outcomes

Primary

Measure	Time frame	Description
Central Visual Acuity	3 months	Pre and Post Procedure Visual Acuity

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026